Scrip
Boehringer Ingelheim pins hopes on Pradaxa to boost sales
27 April 2009
Sita Shah
Please Login to read the full article.
27 April 2009
Sita Shah
sita.shah@informa.com
Boehringer Ingelheim is targeting its anticoagulant Pradaxa (dabigatran etexilate) to drive future sales as Flomax (tamsulosin hydrochloride) and Mirapex (pramipexole dihydrochloride) face patent expiries in 2010.
The German company, one of the world's largest privately owned pharmaceutical...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Bayer's anticoagulant rivaroxaban non-inferior to standard therapy in Phase III DVT trial
- Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
- Xarelto stumbles on filing update but shines in long-term treatment for VTE risk reduction
- Bristol-Myers Squibb stops Phase III trial of apixaban on "clear evidence" of efficacy
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
